2018
Long-term outcomes of mitral regurgitation by type and severity
Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, Alexander JH, Kisslo JA, Wang A, Mark DB, Velazquez EJ. Long-term outcomes of mitral regurgitation by type and severity. American Heart Journal 2018, 203: 39-48. PMID: 30015067, DOI: 10.1016/j.ahj.2018.05.001.Peer-Reviewed Original ResearchConceptsMR severityCause deathIschemic MRSurvival rateCause death riskCoronary artery diseaseLong-term outcomesAbsolute mortality ratesQualifying patientsArtery diseaseEchocardiography studyMitral regurgitationVentricular sizeIndeterminate causeBaseline severityDeath riskSevere MREchocardiography laboratoryHigh riskMortality rateClinical settingPatientsValve morphologySeverityMyxomatous
2014
Blood pressure level impacts risk of death among HIV seropositive adults in Kenya: a retrospective analysis of electronic health records
Bloomfield GS, Hogan JW, Keter A, Holland TL, Sang E, Kimaiyo S, Velazquez EJ. Blood pressure level impacts risk of death among HIV seropositive adults in Kenya: a retrospective analysis of electronic health records. BMC Infectious Diseases 2014, 14: 284. PMID: 24886474, PMCID: PMC4046023, DOI: 10.1186/1471-2334-14-284.Peer-Reviewed Original ResearchConceptsSystolic blood pressureLower blood pressureHigher systolic blood pressureCardiovascular risk factorsBlood pressure levelsBlood pressureHigh blood pressureHigher mortality riskMortality rateHazard ratioRisk factorsIncidence rateRetrospective analysisMortality riskLarge HIV treatment programHuman immunodeficiency virus (HIV) infectionNormal systolic blood pressureProportional hazards regression modelsCox proportional hazards modelAdvanced HIV diseaseNon-communicable causeHIV-seropositive individualsHIV-seropositive adultsImmunodeficiency virus infectionHIV treatment programs
2009
Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial)
Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). The American Journal Of Cardiology 2009, 104: 151-157. PMID: 19576338, DOI: 10.1016/j.amjcard.2009.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanConceptsBeta blockersHeart failureMyocardial infarctionBaseline characteristicsAcute Myocardial Infarction trialAngiotensin receptor blocker valsartanCombination of valsartanNonfatal cardiovascular eventsAngiotensin receptor blockersBeta-blocker useMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsRisk of deathSignificant survival advantageCardiovascular eventsSystolic dysfunctionVentricular dysfunctionVentricular functionSurvival advantageLower riskPatientsMortality rateBlockersValsartan
2007
Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings
Bourque JM, Velazquez EJ, Tuttle RH, Shaw LK, O’Connor C, Borges-Neto S. Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings. Journal Of Nuclear Cardiology 2007, 14: 165-173. PMID: 17386378, DOI: 10.1016/j.nuclcard.2006.11.011.Peer-Reviewed Original ResearchConceptsMortality riskEjection fractionPrognostic informationHigher long-term mortality ratesLong-term mortality ratesPerfusion single-photon emissionVentricular ejection fractionIschemic heart diseaseLong-term outcomesProportional hazard modelingLong-term survivalSingle photon emissionCardiac catheterizationNormal LVEFRisk stratificationPerfusion findingsPatient prognosticationHeart diseaseRest scoreLVEFMyocardial perfusionMortality ratePerfusion studiesHazard modelingSignificant predictors
2003
Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?
Bourque JM, Velazquez EJ, Borges-Neto S, Shaw LK, Whellan DJ, O’Connor C. Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? American Heart Journal 2003, 145: 758-767. PMID: 12766731, DOI: 10.1016/s0002-8703(02)94818-0.Peer-Reviewed Original ResearchMeSH KeywordsCoronary DiseaseFemaleFluorodeoxyglucose F18Heart FailureHumansMaleMyocardial RevascularizationProspective StudiesRadiopharmaceuticalsRetrospective StudiesSurvival RateThallium RadioisotopesTomography, Emission-ComputedTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftConceptsSignificant coronary artery diseaseCoronary artery diseaseLong-term mortalityArtery diseaseSurvival rateHeart failureTreatment strategiesImpaired left ventricular functionLong-term mortality ratesIschemic heart failureLeft ventricular functionIntermediate survival ratesNuclear imaging studiesLack of randomizationLower survival rateEjection fractionVentricular functionViable myocardiumReferral biasStudy protocolTreatment allocationLarge cohortPrognostic studiesMortality ratePatients